Clinical Trial Update: VEC-162 Study in Adult Patients With Primary Insomnia [Phase 3]

View source ↗

Summary

Phase 3 trial update for VEC-162 in adults with primary insomnia; the study completed and results were posted in October 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• VEC-162

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Primary Insomnia | Phase 3 | Status: COMPLETED | Results posted: 2014-10-15